Organogenesis Holdings Inc Revenue Growth Rates (ORGO), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Organogenesis Holdings Inc   (NASDAQ: ORGO)
 

ORGO's Revenue Growth by Quarter and Year

Organogenesis Holdings Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ORGO Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 43.76
1st Quarter March 37.23
FY 80.99

ORGOs Annual Revenue
Organogenesis Holdings Inc 's Revenue in the fiscal year 2025 $ 564.17 millions
Organogenesis Holdings Inc 's Revenue in the fiscal year 2024 $ 482.04 millions
Organogenesis Holdings Inc 's Revenue in the fiscal year 2023 $ 433.14 millions
Organogenesis Holdings Inc 's Revenue in the fiscal year 2022 $ 450.89 millions
Organogenesis Holdings Inc 's Revenue in the fiscal year 2021 $ 468.06 millions




ORGO Revenue second quarter 2026 Y/Y Growth Comment
Organogenesis Holdings Inc reported drop in Revenue in the second quarter 2026 by -56.68% to $ 43.76 millions, from the same quarter in 2025.
The fall in the second quarter 2026 Organogenesis Holdings Inc 's Revenue compares unfavorably to the Company's average Revenue increase of 11.9%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 175 other companies have achieved higher Revenue growth. While Organogenesis Holdings Inc ' s Revenue meltdown of -56.68% ranks overall at the positon no. 3780 in the second quarter 2026.


ORGO Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 78.12 % 27.1 % -12.98 %
3rd Quarter September - 30.98 % 6.13 % -7.13 %
2nd Quarter June -56.68 % -22.44 % 11 % -3.36 %
1st Quarter March -57.05 % -21.18 % 2.17 % 10.83 %
FY   - 17.04 % 11.29 % -

Financial Statements
Organogenesis Holdings Inc 's second quarter 2026 Revenue $ 43.76 millions ORGO's Income Statement
Organogenesis Holdings Inc 's second quarter 2025 Revenue $ 101.01 millions Quarterly ORGO's Income Statement


ORGO Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 49.55 % 9.97 % -8.18 %
3rd Quarter September - 49.35 % -11.56 % -7.49 %
2nd Quarter June 17.53 % 16.52 % 18.41 % 8.99 %
1st Quarter March -83.5 % -31.56 % 10.37 % -6.01 %
FY (Year on Year)   - 17.04 % 11.29 % -


Back to ORGO Growth rate Comparisons >> Back to ORGO Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #176
Healthcare Sector #528
Overall #3780

Revenue Y/Y Growth Statistics
High Average Low
78.65 % 11.9 % -57.06 %
(Jun 30 2021)   (Mar 31 2024)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #176
Healthcare Sector #528
Overall #3780
Revenue Y/Y Growth Statistics
High Average Low
78.65 % 11.9 % -57.06 %
(Jun 30 2021)   (Mar 31 2024)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Organogenesis Holdings Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
49.54 % 4.83 % -83.5 %
(Dec 31 2025)  


ORGO's II. Quarter Q/Q Revenue Comment
Organogenesis Holdings Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 17.53%, to $ 43.76 millions, from $37.23 millions in the first quarter.
ORGO is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 48 other companies have achieved higher Revenue quarter on quarter growth. While Organogenesis Holdings Inc 's Revenue growth quarter on quarter, overall rank is 564.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #49
Healthcare Sector #105
Overall #564
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #49
Healthcare Sector #105
Overall #564
Revenue Q/Q Growth Statistics
High Average Low
49.54 % 4.83 % -83.5 %
(Dec 31 2025)  


ORGO's II. Quarter Q/Q Revenue Comment
Organogenesis Holdings Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 17.53%, to $ 43.76 millions, from $37.23 millions in the first quarter.
ORGO is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 48 other companies have achieved higher Revenue quarter on quarter growth. While Organogenesis Holdings Inc 's Revenue growth quarter on quarter, overall rank is 564.


Organogenesis Holdings Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 457.45 $ 514.70 $ 564.17 $ 465.22 $ 429.53
Y / Y Revenue Growth (TTM) 6.5 % 12.19 % 17.04 % 2.24 % -4.21 %
Year on Year Revenue Growth Overall Ranking # 2945 # 1639 # 773 # 1575 # 2099
Seqeuential Revenue Change (TTM) -11.12 % -8.77 % 21.27 % 8.31 % -6.37 %
Seq. Revenue Growth (TTM) Overall Ranking # 3045 # 2524 # 1197 # 1578 # 1685


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Organogenesis Holdings Inc 's cumulative twelve months Revenue were $ 457 millions, company would post below average annual Revenue growth of -6.37% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Organogenesis Holdings Inc 's Revenue growth from the 37.23% growth in Mar 31 2026.

In the Healthcare sector 410 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1639 to 2945.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 134
Healthcare Sector # 411
Overall # 2945

Revenue TTM Y/Y Growth Statistics
High Average Low
60.74 %
 14.53 %
-5.42 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 134
Sector # 417
S&P 500 # 3045
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Organogenesis Holdings Inc 's cumulative twelve months Revenue were $ 457 millions, company would post below average annual Revenue growth of -5.42% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Organogenesis Holdings Inc 's Revenue growth from the 37.23% growth in Mar 31 2026.

In the Healthcare sector 410 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1639 to 2945.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 134
Healthcare Sector # 411
Overall # 2945

Revenue TTM Y/Y Growth Statistics
High Average Low
60.74 %
14.53 %
-5.42 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 134
Sector # 417
S&P 500 # 3045




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ORGO's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Bio rad Laboratories Inc -0.05%$ -0.046 millions
Seer Inc -0.29%$ -0.289 millions
Dyadic International Inc -0.57%$ -0.568 millions
Teva Pharmaceutical Industries Limited-0.81%$ -0.814 millions
Aytu Biopharma Inc-0.91%$ -0.911 millions
Neuropace Inc -1.32%$ -1.323 millions
Ardent Health Inc -1.40%$ -1.400 millions
Sunshine Biopharma Inc -1.56%$ -1.557 millions
Pacific Biosciences Of California Inc -1.71%$ -1.706 millions
United Therapeutics Corporation-1.92%$ -1.916 millions
Orasure Technologies Inc-1.93%$ -1.930 millions
Pulmonx Corporation-1.93%$ -1.931 millions
Volitionrx Limited-1.97%$ -1.975 millions
Organon and Co -2.26%$ -2.258 millions
Airsculpt Technologies Inc -2.53%$ -2.527 millions
Charles River Laboratories International inc -2.72%$ -2.718 millions
Perrigo Company Plc-3.17%$ -3.171 millions
Zai Lab Limited-3.33%$ -3.333 millions
Vanda Pharmaceuticals Inc -3.92%$ -3.919 millions
Teladoc Health Inc -3.95%$ -3.952 millions
Dentsply Sirona Inc -4.06%$ -4.060 millions
Sanuwave Health Inc -4.18%$ -4.181 millions
Treace Medical Concepts Inc -4.24%$ -4.244 millions
Fortrea Holdings Inc -4.52%$ -4.519 millions
Positron Corporation-6.91%$ -6.907 millions
Standard Biotools Inc -7.05%$ -7.046 millions
Inspire Medical Systems inc -7.32%$ -7.316 millions
Adapthealth Corp -7.50%$ -7.505 millions
China Pharma Holdings Inc-7.55%$ -7.548 millions
Skinhealth Systems Inc -7.68%$ -7.680 millions


About Organogenesis Holdings Inc Revenue Growth Rates (ORGO), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Organogenesis Holdings Inc (CIK 1661181).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-338049
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Organogenesis Holdings Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.